組織診断：各種技術と世界市場

世界の組織診断の市場規模は、2024年の89億米ドルから、予測期間中はCAGR 7.0％で推移し、2029年には124億米ドルに達すると予測されています。

組織診断用試薬の部門は、2024年の66億米ドルから、予測期間中はCAGR 6.9%で推移し、2029年には93億米ドルに達すると予測されています。アジア太平洋市場は、2024年の22億米ドルから、CAGR 7.0%で推移し、2029年には31億米ドルに達すると予測されます。

当レポートでは、世界の組織診断の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 市場概要と定義
• 免疫組織化学 (IHC)
• In Situハイブリダイゼーション
• ポリメラーゼ連鎖反応
• 次世代シーケンシング
• 一般培養検査

第3章 市場力学

• 市場力学
• 市場促進要因
• 癌発症率の増加
• 癌治療におけるコンパニオン診断
• 早期癌検査の重要性
• 癌の初期症状への意識の向上
• 高齢化社会
• 市場機会
• アクセスの強化
• デジタル病理
• パートナーシップ
• 市場抑制要因
• 組織診断検査の費用
• 競合技術
• 所要時間
• 市場の課題
• 熟練した専門家の不足
• 複雑なサンプル調製と取り扱い

第4章 新興技術と開発

• 概要
• デジタル病理とAIの統合
• 3D組織病理とAI
• 蛍光in situシーケンシング

第5章 組織診断検査市場

• セグメンテーションの内訳
• 市場内訳
• 市場内訳：製品タイプ別
• 市場内訳：技術別
• 市場内訳：セグメント別
• 組織病理市場
• 分子病理市場
• 微生物検査市場
• デジタル病理市場
• 市場内訳：用途別
• 市場内訳：エンドユーザー別
• 地理的内訳
• 市場内訳：地域別
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• その他の地域

第6章 競合情報

• 業界シナリオ
• 競合情勢

第7章 組織診断市場における持続可能性：ESGの観点

• ESG：イントロダクション
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• BCCによる総論

第8章 付録

• 調査手法
• 参考文献
• 頭字語
• 企業プロファイル
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BD
• BIOCARE MEDICAL LLC.
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• MERCK KGAA
• MYRIAD GENETICS INC.
• QIAGEN
• THERMO FISHER SCIENTIFIC INC.
• ZYTOVISION GMBH

List of Tables

• Summary Table : Global Tissue Diagnostics Market, by Product Type, Through 2029
• Table 1 : Global Incidence of All Cancers, by Region, 2022-2045
• Table 2 : Cancer Cases, by Country, 2022
• Table 3 : Incidence of Cancer, by Cancer Type, 2022
• Table 4 : Cancer Treatments Based on Specific Tests
• Table 5 : Global Tissue Diagnostics Market, Through 2029
• Table 6 : Global Tissue Diagnostics Market, by Product Type, Through 2029
• Table 7 : Global Tissue Diagnostics Market, by Technology, Through 2029
• Table 8 : Global IHC Tissue Diagnostics Market, by Region, Through 2029
• Table 9 : Global H&E and Special Stains Diagnostics Market, by Region, Through 2029
• Table 10 : Global ISH Tissue Diagnostics Market, by Region, Through 2029
• Table 11 : Global PCR Tissue Diagnostics Market, by Region, Through 2029
• Table 12 : Global NGS Tissue Diagnostics Market, by Region, Through 2029
• Table 13 : Global Digital Pathology Market, by Region, Through 2029
• Table 14 : Global Tissue Diagnostics Market, by Segment Type, Through 2029
• Table 15 : Global Histopathology Market, by Product Type, Through 2029
• Table 16 : Global Histopathology Market, by Region, Through 2029
• Table 17 : Global Molecular Pathology Market, by Product Type, Through 2029
• Table 18 : Global Molecular Pathology Market, by Region, Through 2029
• Table 19 : Global Microbiology Testing Market, by Product Type, Through 2029
• Table 20 : Global Microbiology Testing Market, by Region, Through 2029
• Table 21 : Global Digital Pathology Market, Through 2029
• Table 22 : Global Digital Pathology Market, by Region, Through 2029
• Table 23 : Global Tissue Diagnostics Market, by Application, Through 2029
• Table 24 : Global Tissue Diagnostics Market, by End User, Through 2029
• Table 25 : Global Tissue Diagnostics Market, by Region, Through 2029
• Table 26 : North American Tissue Diagnostics Market, by Country, Through 2029
• Table 27 : European Tissue Diagnostics Market, by Country, Through 2029
• Table 28 : Asia-Pacific Tissue Diagnostics Market, by Country, Through 2029
• Table 29 : Latin American Tissue Diagnostics Market, by Country, Through 2029
• Table 30 : RoW Tissue Diagnostics Market, Through 2029
• Table 31 : ESG: Environmental Overview
• Table 32 : ESG: Social Overview
• Table 33 : ESG: Governance Overview
• Table 34 : Acronyms Used in this Report
• Table 35 : Abbott: Company Snapshot
• Table 36 : Abbott: Financial Performance, FY 2022 and 2023
• Table 37 : Abbott: Product Portfolio
• Table 38 : Agilent Technologies Inc.: Company Snapshot
• Table 39 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
• Table 40 : Agilent Technologies Inc.: Product Portfolio
• Table 41 : Agilent Technologies Inc.: News/Key Developments, 2024
• Table 42 : BD: Company Snapshot
• Table 43 : BD: Financial Performance, FY 2022 and 2023
• Table 44 : BD: Product Portfolio
• Table 45 : Biocare Medical LLC.: Company Snapshot
• Table 46 : Biocare Medical LLC.: Product Portfolio
• Table 47 : Biomerieux: Company Snapshot
• Table 48 : Biomerieux: Financial Performance, FY 2022 and 2023
• Table 49 : Biomerieux: Product Portfolio
• Table 50 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 51 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
• Table 52 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 53 : Danaher Corp.: Company Snapshot
• Table 54 : Danaher Corp.: Financial Performance, FY 2022 and 2023
• Table 55 : Danaher Corp.: Product Portfolio
• Table 56 : Danaher Corp.: News/Key Developments, 2023
• Table 57 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 58 : F. Hoffmann-La Roche Ltd.: Financials, FY 2022 and 2023
• Table 59 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 60 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
• Table 61 : Illumina Inc.: Company Snapshot
• Table 62 : Illumina Inc.: Financial Performance, FY 2022 and 2023
• Table 63 : Illumina Inc.: Product Portfolio
• Table 64 : Illumina Inc.: News/Key Developments, 2024
• Table 65 : Koninklijke Philips N.V.: Company Snapshot
• Table 66 : Koninklijke Philips N.V.: Financial Performance, FY 2022 and 2023
• Table 67 : Koninklijke Philips N.V.: Product Portfolio
• Table 68 : Merck KGaA: Company Snapshot
• Table 69 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 70 : Merck KGaA: Product Portfolio
• Table 71 : Myriad Genetics Inc.: Company Snapshot
• Table 72 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
• Table 73 : Myriad Genetics Inc.: Product Portfolio
• Table 74 : QIAGEN.: Company Snapshot
• Table 75 : QIAGEN.: Financial Performance, FY 2022 and 2023
• Table 76 : QIAGEN.: Product Portfolio
• Table 77 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 78 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 79 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 80 : ZytoVision GmbH: Company Snapshot
• Table 81 : ZytoVision GmbH: Product Portfolio

List of Figures

• Summary Figure A : Global Tissue Diagnostics Market, by Product Type, 2021-2029
• Summary Figure B : Shares of Global Market for Tissue Diagnostics, by Product Type, 2023
• Figure 1 : Market Dynamics of Tissue Diagnostics
• Figure 2 : Shares of All Cancer Cases, by Region, 2022
• Figure 3 : Emerging Trends and Technologies in Tissue Diagnostics
• Figure 4 : Shares of Global Market for Tissue Diagnostics, by Technology, 2023
• Figure 5 : Shares of Global Market for Tissue Diagnostics, by Segment Type, 2023
• Figure 6 : Shares of Global Market for Histopathology, by Product Type, 2023
• Figure 7 : Shares of Global Market for Molecular Pathology, by Product Type, 2023
• Figure 8 : Shares of Global Market for Microbiology Testing, by Product Type, 2023
• Figure 9 : Shares of Global Market for Tissue Diagnostics, by Application, 2023
• Figure 10 : Shares of Global Market for Tissue Diagnostics, by End User, 2023
• Figure 11 : Shares of Global Market for Tissue Diagnostics, by Region, 2023
• Figure 12 : Shares of North American Market for Tissue Diagnostics, by Country, 2023
• Figure 13 : Shares of European Market for Tissue Diagnostics, by Country, 2023
• Figure 14 : Shares of Asia-Pacific Market for Tissue Diagnostics, by Country, 2023
• Figure 15 : Shares of Latin American Tissue Diagnostics Market, by Country, 2023
• Figure 16 : Shares of Global Market for Tissue Diagnostics, by Company, 2023
• Figure 17 : ESG Pillars
• Figure 18 : Advantages of ESG for Companies
• Figure 19 : Abbott: Revenue Shares, by Business Unit, FY 2023
• Figure 20 : Abbott: Revenue Shares, by Country/Region, FY 2023
• Figure 21 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 22 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 23 : BD: Revenue Shares, by Business Unit, FY 2023
• Figure 24 : BD: Revenue Shares, by Country/Region, FY 2023
• Figure 25 : Biomerieux: Revenue Shares, by Business Unit, FY 2023
• Figure 26 : Biomerieux: Revenue Shares, by Country/Region, FY 2023
• Figure 27 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 28 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 29 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 30 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 31 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 32 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
• Figure 33 : Illumina Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 34 : Illumina Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 35 : Koninklijke Philips N.V.: Revenue Shares, by Business Unit, FY 2023
• Figure 36 : Koninklijke Philips N.V.: Revenue Shares, by Country/Region, FY 2023
• Figure 37 : Merck KGaA: Market Shares, by Business Unit, FY 2023
• Figure 38 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
• Figure 39 : Myriad Genetics Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 40 : Myriad Genetics Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 41 : QIAGEN.: Revenue Shares, by Business Unit, FY 2023
• Figure 42 : QIAGEN.: Revenue Shares, by Country/Region, FY 2023
• Figure 43 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 44 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2023

The global market for tissue diagnostics is estimated to increase from $8.9 billion in 2024 to reach $12.4 billion by 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 through 2029.

The reagents market for tissue diagnostics is estimated to increase from $6.6 billion in 2024 to reach $9.3 billion by 2029, at a CAGR of 6.9% from 2024 through 2029.

The instruments market for tissue diagnostics is estimated to increase from $2.2 billion in 2024 to reach $3.1 billion by 2029, at a CAGR of 7.0% from 2024 through 2029.

Report Scope

The report provides an analysis of the tissue diagnostics market, along with a competitive landscape and profiles of leading companies that include their revenues, product portfolios and recent activities. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services. Organizations, distributors and exporters should find useful information about market developments and trends.

The study segments the market on multiple bases. By product type, the market is segmented into instruments and reagents (reagents/test kits/consumables of tissue diagnostics).

By segment type, the market is divided into histopathology, which includes hematoxylin and eosin stains (H&E) and immunohistochemistry (IHC); molecular pathology, which includes in situ hybridization (ISH), polymerase chain reaction (PCR) and next-generation sequencing (NGS); microbiological testing, which includes general culture testing and antimicrobial susceptibility testing and identification (AST/ID); and digital pathology.

Regional market analysis is provided for all the major segments. The regions are North America; Europe; Asia-Pacific; Latin America; and Rest of the World (RoW), which in this report consists of the Middle East and Africa. The report also provides country-level analyses of markets and market segments.

The report covers only tissue sample-based tests. The liquid biopsy market; swab, saliva and urine-based tests; and the service testing market of tissue diagnostics are outside the scope of the report.

In this report, the tissue diagnostics market is segmented by:

Product type:

• Reagents.
• Instruments.

Segments:

• Histopathology (H&E, IHC).
• Molecular pathology (ISH, PCR and NGS).
• Microbiological testing (general culture testing, AST/ID testing) .
• Digital pathology.

Technology:

• H&E.
• IHC.
• ISH.
• PCR.
• NGS.
• Digital pathology.

Applications:

• Oncology.
• Tissue typing.
• Pathogen detection and AST.

End users:

• Professional laboratories.
• Emergency care units.
• Academic and research institutes.

Report Includes

• 40 data tables and 42 additional tables
• An analysis of the global market trends for tissue diagnostics, with market revenue data from 2022 to 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by type of test, technology, application, end user and region
• Facts and figures pertaining to the market dynamics, technical advances, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• An analysis of patents, emerging trends and developments in the industry
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Illumina Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Market Overview and Definitions
• Immunohistochemistry (IHC)
• In Situ Hybridization
• Polymerase Chain Reaction
• Next-Generation Sequencing
• General Culture Testing

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Cancer Cases
• Companion Diagnostics in Cancer Treatment
• Importance of Early Cancer Testing
• Raising Awareness of Early Signs of Cancer
• Aging Population
• Market Opportunities
• Enhancing Access
• Digital Pathology
• Partnerships
• Market Restraints
• Cost of Tissue Diagnostic Tests
• Competing Technologies
• Turnaround Time
• Market Challenges
• Lack of Skilled Professionals
• Complex Sample Preparation and Handling

Chapter 4 Emerging Technologies and Developments

• Overview
• Digital Pathology and AI Integration
• 3D Tissue Pathology and AI
• Fluorescent In Situ Sequencing

Chapter 5 Tissue Diagnostics Testing Market

• Segmentation Breakdown
• Market Breakdown
• Market Breakdown, by Product Type
• Market Breakdown, by Technology
• Market Breakdown, by Segment
• Histopathology Market
• Molecular Pathology Market
• Microbiology Testing Market
• Digital Pathology Market
• Market Breakdown, by Application
• Market Breakdown, by End User
• Geographic Breakdown
• Market Breakdown, by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest of the World

Chapter 6 Competitive Intelligence

• Industry Scenario
• Competitive Landscape

Chapter 7 Sustainability in the Market for Tissue Diagnostics: An ESG Perspective

• Introduction to ESG
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 8 Appendix

• Research Methodology
• References
• Acronyms
• Company Profiles
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BD
• BIOCARE MEDICAL LLC.
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• MERCK KGAA
• MYRIAD GENETICS INC.
• QIAGEN
• THERMO FISHER SCIENTIFIC INC.
• ZYTOVISION GMBH